Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety and Efficacy of Tulisokibart in Crohn's Disease or Ulcerative Colitis
NCT06651281Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Nov 2024
- Primary completion
- Dec 2037
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial of tulisokibart in Crohn's disease and ulcerative colitis (UC) (4 arms), sponsored by Merck & Co. Primary endpoints: Number of Participants Who Experience an Adverse Event (AE) at 378 weeks and Number of Participants Who Discontinue Study Treatment Due to an AE at 364 weeks. Started Nov 2024; status: recruiting.
02
Drugs
tulisokibart
03
Conditions
Crohn's diseaseulcerative colitis (UC)
Beyond the preview
Go deeper on NCT06651281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06651281.